The GLP-1 Drug, ExENTIDE, has no positive impact on the movement, symptoms or brain imaging of people with parkinson’s, finds a new study by UCL Researchers.

For their research, published in The lancet, The team designed a randomized controlled phase II trial to definately determine where NESS, after smaller studies had suggested the drug may be helps. The study is the world’s largest and longest trial of exanatide in People with Parkinson’s Disease.

A Total of 194 people with Parkinson’s Disease Participated in the TRIAL Across Six Research Hones in the UK, Including in London, Oxford, Plymouth, SALFORD and Edinburgh. They either used exenatide injections on a weekly Basis, or a visually identifying placebo.

The Trial Ran for 96 Weeks and was double blind, meaning that neither the participants, resarchers knew who was received the real treatment or placebo.

At the end of the study period, the researchers found that there was no advantage at any point over the course of 96 weeks in the group using exenatide. And no benefits were shown in the objective examinations of patients, their own reports of symptom severity, or imaging findings.

Lead Author, Professor Thomas Foltynie ECECTED by Parkinson’s Disease and the Parkinson’s Disease Research Community. “

GLP-1 Drugs-Such as Semaglutide (Wegovy) and OzEMPIC-HAVE BECOME Increasingly Popular Over Recent Years and There has been an enormous interest in their potental health benefits.

For example, semaglutide (wegovy) can be used as a treatment for type 2 diabetes along with a licensed weight loss drug.

Meanwhile, Older Members of the Drug Class – Such as Exenatide and Lixisenatide – Have Parkinson’s disease.

Professor Foltynie Added, “It is not yet clear where Ether abnormal blood test results such as having ‘pre -Diabetes’ Might predict a better response to exenatide, and behtra there was more of these people in the earlier, smaller trials in which we found positive overall effects. “

The Trial Took Place at the UCL Queen Square Institute of Neurology and the UCLH National Hospital for Neurology and Neurosourgery.

There was a high level of participant rejection through the trial and the research team has confirmed high levels of compliance with the medicine by the use of Blood Tests, the Levels of Exain El of confidence in the results.